Latest News and Press Releases

Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 and more robust data in 2024 CTA submitted for...

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five...

Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection ...

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...

Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with...

Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression ...

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic...

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year SC291 granted Fast Track Designation by the FDA for the treatment...

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...